Similar efficacy was observed across germline and somatic BRCA alterations, as well as between BRCA1 and BRCA2 subgroups, with higher PSA responses noted in BRCA2-mutated cases; the most common grade ≥ 3 adverse event was anemia (25%) as shown in Table 3 [169]. The gene discussed is BRCA2; the disease is anemia (phenotype).